130 related articles for article (PubMed ID: 35307103)
1. The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC.
Wang F; Zhou Q
J Thorac Oncol; 2022 Apr; 17(4):481-486. PubMed ID: 35307103
[No Abstract] [Full Text] [Related]
2. And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC.
Lau SCM; Ou SI
J Thorac Oncol; 2022 Oct; 17(10):1144-1154. PubMed ID: 36192074
[No Abstract] [Full Text] [Related]
3. Lazertinib: First Approval.
Dhillon S
Drugs; 2021 Jun; 81(9):1107-1113. PubMed ID: 34028784
[TBL] [Abstract][Full Text] [Related]
4. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
Ahn MJ; Han JY; Lee KH; Kim SW; Kim DW; Lee YG; Cho EK; Kim JH; Lee GW; Lee JS; Min YJ; Kim JS; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Kim HT; Lee DH; Kim S; Cho BC
Lancet Oncol; 2019 Dec; 20(12):1681-1690. PubMed ID: 31587882
[TBL] [Abstract][Full Text] [Related]
5. Third-generation EGFR-TKIs—a new hope for NSCLC.
Akkermans R
Lancet Respir Med; 2014 Jul; 2(7):520. PubMed ID: 25140365
[No Abstract] [Full Text] [Related]
6. EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation.
Park S; Ku BM; Jung HA; Sun JM; Ahn JS; Lee SH; Park K; Ahn MJ
Cancer Res Treat; 2020 Oct; 52(4):1288-1290. PubMed ID: 32599977
[TBL] [Abstract][Full Text] [Related]
7. [Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].
Ni L; Nie L
Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):110-115. PubMed ID: 29526178
[TBL] [Abstract][Full Text] [Related]
8. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
Zhang YC; Chen ZH; Zhang XC; Xu CR; Yan HH; Xie Z; Chuai SK; Ye JY; Han-Zhang H; Zhang Z; Bai XY; Su J; Gan B; Yang JJ; Li WF; Tang W; Luo FR; Xu X; Wu YL; Zhou Q
EBioMedicine; 2019 May; 43():180-187. PubMed ID: 31027916
[TBL] [Abstract][Full Text] [Related]
9. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
10. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years.
Vansteenkiste J; Wauters E
Ann Oncol; 2018 Jan; 29(suppl_1):i1-i2. PubMed ID: 29462258
[No Abstract] [Full Text] [Related]
12. [Treatment of advanced NSCLC with unknown EGFR gene status
--TKI or chemotherapy?].
Liu X; Xu J
Zhongguo Fei Ai Za Zhi; 2014 Oct; 17(10):709-14. PubMed ID: 25342036
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
14. Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
Tartarone A; Lerose R; Lazzari C; Gregorc V; Aieta M
Med Oncol; 2014 Aug; 31(8):78. PubMed ID: 24958518
[TBL] [Abstract][Full Text] [Related]
15. The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation.
Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciadiello F; Gridelli C
Curr Med Chem; 2012; 19(20):3337-52. PubMed ID: 22664249
[TBL] [Abstract][Full Text] [Related]
16. [Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer].
Zhou M; Chen DM; Xia L; Song YY; Shi YK; Yang ZM
Zhonghua Zhong Liu Za Zhi; 2019 Dec; 41(12):949-952. PubMed ID: 31874554
[TBL] [Abstract][Full Text] [Related]
17. Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer.
Inoue A
Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(7):266-272. PubMed ID: 32788550
[TBL] [Abstract][Full Text] [Related]
18. Irreversible EGFR inhibitors in the treatment of advanced NSCLC.
Maione P; Rossi A; Bareschino M; Sacco PC; Schettino C; Casaluce F; Sgambato A; Gridelli C
Curr Pharm Des; 2014; 20(24):3894-900. PubMed ID: 24138713
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population.
Sutandyo N; Hanafi A; Jayusman M
Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):562-567. PubMed ID: 31526459
[TBL] [Abstract][Full Text] [Related]
20. Furmonertinib: First Approval.
Deeks ED
Drugs; 2021 Oct; 81(15):1775-1780. PubMed ID: 34528187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
